Journal
VISION RESEARCH
Volume 48, Issue 3, Pages 319-324Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.visres.2007.07.012
Keywords
nanoparticle; ocular gene therapy; gene transfer; non-viral therapy; retinal degeneration; vector design
Categories
Funding
- NEI NIH HHS [R03 EY016201, R01 EY018656, R03 EY016201-01A1, R03 EY016201-02, R01 EY018656-01, R01 EY010609, R01 EY010609-12] Funding Source: Medline
Ask authors/readers for more resources
The use of nanoparticles as carriers for the delivery of therapeutic materials to target tissues has became popular in recent years and has demonstrated great potentials for the treatments of a wide range of diseases. In this review, we summarize the advantages of nanotechnology as a common gene delivery strategy with emphasis on ocular therapy. Particular attention is paid to the CK30-PEG compacted DNA nanoparticles that have been successfully tested in the eye, lung, and brain. These particles resulted in higher transfection efficiency and longer duration of expression than other non-viral vectors without any toxicity or other side effects. They have been safely used clinically and are efficient for a broad range of gene therapy applications. The review also discusses mechanisms of nanoparticle uptake and internalization by cells, obstacles and limitations to the use of this technology, as well as novel methodologies to optimize nanoparticle driven gene expression. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available